19 Aug Sprout Pharmaceuticals Receives FDA Approval for Addyi™
Building a Breakthrough Brand:
Yesterday, in a pivotal moment for womens’ sexual health medicine, Sprout Pharmaceuticals‘ new drug, Addyi™ received FDA approval.
Addyi™ treats a condition known as HSDD, or hypoactive sexual desire disorder.
We have had the privilege of working with Sprout Pharmaceuticals since early 2012, developing their brand, as well as the Addyi™ identity. Our in-house brand team is responsible for the creation and maintenance of their visual identity, promotional collateral, product packaging, press imagery, photography, and many other components that have shaped the Raleigh, NC firm’s efforts in getting this drug approved, and to market.
“It has been a remarkable journey to get to this breakthrough moment. Today we celebrate what this approval means for all women who have long awaited a medical treatment option for this life impacting condition,” said Cindy Whitehead, chief executive officer of Sprout. “We applaud the FDA for putting the patient voice at the center of the conversation and for focusing on scientific evidence.”
-Cindy Whitehead, CEO Sprout Pharmaceuticals
Sprout and Addyi™ brand content has since spread to almost every major news outlet around the world, including the BBC, Reuters, CNN, Fox News, The NY Times, The Wall Street Journal, Forbes, and others.